Precancerous lesions of gastric cancer (PLGC) represent a critical stage in gastric carcinogenesis. Animal models are widely used to simulate human pathologies in the laboratory, and the establishment of PLGC animal models is essential for investigating therapeutic strategies for precancerous gastric lesions. This study describes a method for establishing a PLGC model in male Sprague-Dawley (SD) rats using a multifactorial induction approach. Rats were administered 200 µg/mL N-methyl-N'-nitro-N-nitrosoguanidine at a fixed time each day (freshly prepared and protected from light), with fasting on alternate days (1 day feeding/1 day fasting, with free access to water). On fasting days, 2% sodium salicylate was administered by gastric gavage (10 mL/kg/day). At week 32, hematoxylin and eosin (HE) staining of the gastric mucosa in the model group revealed thinning of the gastric mucosa and a reduced number of glands. Alcian blue-periodic acid-Schiff (AB-PAS) staining indicated the presence of intestinal metaplasia. Immunohistochemical analysis demonstrated increased expression of MUC2. These findings confirmed the successful establishment of the PLGC model. This model provides a valuable tool for studying the pathogenesis and treatment of precancerous lesions of gastric cancer.

ETHNOPHARMACOLOGICAL RELEVANCE:Bazi Bushen Capsule (BZBS), a traditional Chinese medicine formulation composed of multiple bioactive herbal components, has been validated in multicenter randomized double-blind controlled trials for its potent anti-aging properties. Previous studies from our group have demonstrated that BZBS effectively restores gut microbiota homeostasis and attenuates the impairment of intestinal barrier function, thereby ameliorating age-related cognitive decline. However, the specific molecular mechanisms by which BZBS modulates key microbial-metabolite networks to delay brain aging remain poorly understood and warrant further investigation. AIM OF THE STUDY:This study aims to elucidate the key microbiota-metabolite networks through which BZBS improves cognitive function and delays brain aging in senescence-accelerated mouse-prone 8 (SAMP8) mice. MATERIALS AND METHODS:Eight-week-old male SAMP8 mice were used as experimental models, randomly divided into Model, BZ-low (0.5 g/kg/d BZBS), BZ-high (1 g/kg/d BZBS), and RAPA (2 mg/kg/d rapamycin) groups. Senescence-accelerated mouse resistant 1 (SAMR1) mice served as the control group. Cognitive function was assessed using the Barnes Maze test and the three-chamber social test. The structural damage and pathological changes in the brain tissue were evaluated through transcranial Doppler, micro-computed tomography, Nissl staining, and Western blot analysis. Next, the intestinal barrier function was detected by hematoxylin-eosin (HE) staining, periodic acid-Schiff (PAS) staining, and immunofluorescence (IF) staining. Characteristic bacteria were identified by 16S rRNA sequencing, and metabolomic profiling was performed using non-targeted metabolomics. Akkermansia muciniphila (Akk) was cultured, and fecal microbiota transplantation (FMT) was employed to evaluate its contribution to intestinal barrier function. RESULTS:The study revealed that BZBS therapy not only enhances cognitive capabilities but also restores the intestinal barrier function. Akk was identified as a key regulatory agent mediating the therapeutic effects of BZBS. BZBS administration significantly increased the abundance of Akk and modulated its metabolite profile, particularly components associated with spermidine, thereby reinforcing the intestinal barrier and mitigating age-related cognitive decline. Furthermore, this study demonstrated that Akk, administered via fecal microbiota transplantation, alleviated dextran sulfate sodium (DSS)-induced colitis. CONCLUSION:The results showed that BZBS capsule, a traditional Chinese medicine, may delay brain aging in SAMP8 mice by modulating Akk and its spermidine production.

To explore the intrinsic relationship between benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) and evaluate the therapeutic effects of Bazi Bushen Capsule (BZBS). A model of BPH concomitant with ED was established by using testosterone-supplemented spontaneously hypertensive rats (SHRs). Forty SHRs were divided into 4 groups based on the random number table (n=10 per group), including the model group (SHR+T), the BZBS low-dose group (SHR+T+BZ-low), the BZBS high-dose group (SHR+T+BZ-high), and the finasteride group (SHR+T+Fi). Ten Wistar-Kyoto rats were set up as the control group. Except for the control group, SHRs were subcutaneously injected with 3 mg/kg testosterone, and treated with different therapeutic modalities at the same time for 28 days. The androgen signaling markers related to the prostate, markers of cell proliferation and apoptosis, indicators of corpus cavernosum fibrosis and contraction/relaxation function, inflammatory markers in the prostate and corpus cavernosum tissue were assessed. Network pharmacology analysis was conducted to identify the key therapeutic targets of BZBS and to further validate the experimental findings. BZBS significantly reduced prostate wet weight and prostate index, and improved pathological changes (P<0.01). BZBS modulated expressions of proliferating cell nuclear antigen, Bcl-2-associated X protein, and B-cell lymphoma 2 expression (P<0.05 or P<0.01). BZBS alleviated corpus cavernosum fibrosis, increased the smooth muscle area, upregulated α-smooth muscle actin expression, and improved functional markers—including Ras homolog family member A, Rho-associated coiled-coil containing protein kinase 2, endothelial nitric oxide synthase, nitric oxide, and cyclic guanosine monophosphate (P<0.05 or P<0.01). BZBS also regulated androgen levels, including dihydrotestosterone, 5α-reductase type II, and prostate-specific antigen (P<0.05 or P<0.01). Notably, BZBS effectively attenuated inflammatory responses in both the prostate and corpus cavernosum tissue (P<0.05 or P<0.01). Unlike finasteride—which primarily reduces prostate inflammation—BZBS exhibited a dual therapeutic effect on both BPH and ED. Network pharmacology further suggested that BZBS exerts its effects through multiple inflammation-related targets and pathways. Chronic inflammation plays a crucial role in both BPH and ED. BZBS effectively ameliorates these conditions by modulating inflammatory processes.

Abstract Background Chronic inflammation and metabolic dysfunction are key features of systemic aging, closely associated with the development and progression of age-related metabolic diseases. Bazi Bushen (BZBS), a traditional Chinese medicine used to alleviate frailty, delays biological aging by modulating DNA methylation levels. However, the precise mechanism of its anti-aging effect remains unclear. In this study, we developed the Energy Expenditure Aging Index (EEAI) to estimate biological age. By integrating the EEAI with transcriptome analysis, we aimed to explore the impact of BZBS on age-related metabolic dysregulation and inflammation in naturally aging mice. Methods We conducted indirect calorimetry analysis on five groups of mice with different ages and utilized the data to construct EEAI. 12 -month-old C57BL/6 J mice were treated with BZBS or β-Nicotinamide Mononucleotide (NMN) for 8 months. Micro-CT, Oil Red O staining, indirect calorimetry, RNA sequencing, bioinformatics analysis, and qRT-PCR were performed to investigate the regulatory effects of BZBS on energy metabolism, glycolipid metabolism, and inflammaging. Results The results revealed that BZBS treatment effectively reversed the age-related decline in energy expenditure and enhanced overall metabolism, as indicated by the aging index of energy expenditure derived from energy metabolism parameters across various ages. Subsequent investigations showed that BZBS reduced age-induced visceral fat accumulation and hepatic lipid droplet aggregation. Transcriptomic analysis of perirenal fat and liver indicated that BZBS effectively enhanced lipid metabolism pathways, such as the PPAR signaling pathway, fatty acid oxidation, and cholesterol metabolism, and improved glycolysis and mitochondrial respiration. Additionally, there was a significant improvement in inhibiting the inflammation-related arachidonic acid-linoleic acid metabolism pathway and restraining the IL-17 and TNF inflammatory pathways activated via senescence associated secretory phenotype (SASP). Conclusions BZBS has the potential to alleviate inflammation in metabolic organs of naturally aged mice and maintain metabolic homeostasis. This study presents novel clinical therapeutic approaches for the prevention and treatment of age-related metabolic diseases.

Bazi Bushen (BZBS), a traditional Chinese medicine (TCM), has demonstrated therapeutic efficacy in testicular dysfunction within D-galactose and NaNO2 mouse models. This study aimed to ascertain if BZBS could also mitigate the decline in testicular function associated with natural aging. Therefore, male aged mice were employed to evaluate the preventive effects of BZBS on male reproductive aging. This was achieved by assessing sex hormone production, testicular histomorphology, and spermatogenesis. Relative to the untreated aged control group, BZBS administration elevated the levels of sex hormones and spermatocyte populations and preserved normal testicular structure in aged mice. Notably, spermatogenesis was maintained. Further analyses, including malondialdehyde (MDA) assays and real-time PCR, indicated that BZBS diminished testicular oxidative stress and the inflammatory burden. Corroborating these findings, mice treated with BZBS exhibited reductions in the populations of senescent and apoptotic cells within the seminiferous tubules, suggesting alleviated cellular damage. In contrast, we observed that rapamycin, a drug known for its longevity benefits, induced excessive testicular apoptosis and did not decrease lipid peroxidation. Collectively, our results highlight BZBS’s promising clinical potential in counteracting male reproductive aging, underlining its mechanisms of action.

PurposeThe senescence-accelerated prone mouse 8 (SAMP8) is a widely used model for accelerating aging, especially in central aging. Mounting evidence indicates that the microbiota-gut-brain axis may be involved in the pathogenesis and progression of central aging-related diseases. This study aims to investigate whether Bazi Bushen capsule (BZBS) attenuates the deterioration of the intestinal function in the central aging animal model.MethodsIn our study, the SAMP8 mice were randomly divided into the model group, the BZ-low group (0.5 g/kg/d BZBS), the BZ-high group (1 g/kg/d BZBS) and the RAPA group (2 mg/kg/d rapamycin). Age-matched SAMR1 mice were used as the control group. Next, cognitive function was detected through Nissl staining and two-photon microscopy. The gut microbiota composition of fecal samples was analyzed by 16S rRNA gene sequencing. The Ileum tissue morphology was observed by hematoxylin and eosin staining, and the intestinal barrier function was observed by immunofluorescence. The expression of senescence-associated secretory phenotype (SASP) factors, including P53, TNF-α, NF-κB, IL-4, IL-6, and IL-10 was measured by real-time quantitative PCR. Macrophage infiltration and the proliferation and differentiation of intestinal cells were assessed by immunohistochemistry. We also detected the inflammasome and pyroptosis levels in ileum tissue by western blotting.ResultsBZBS improved the cognitive function and neuronal density of SAMP8 mice. BZBS also restored the intestinal villus structure and barrier function, which were damaged in SAMP8 mice. BZBS reduced the expression of SASP factors and the infiltration of macrophages in the ileum tissues, indicating a lower level of inflammation. BZBS enhanced the proliferation and differentiation of intestinal cells, which are essential for maintaining intestinal homeostasis. BZBS modulated the gut microbiota composition, by which BZBS inhibited the activation of inflammasomes and pyroptosis in the intestine.ConclusionBZBS could restore the dysbiosis of the gut microbiota and prevent the deterioration of intestinal barrier function by inhibiting NLRP3 inflammasome-mediated pyroptosis. These results suggested that BZBS attenuated the cognitive aging of SAMP8 mice, at least partially, by targeting the microbiota-gut-brain axis.

Cardiovascular diseases (CVDs) are one of the most significant diseases that pose a threat to human health. The innovative traditional Chinese medicine Tongxinluo Capsule, developed under the guidance of the theory of traditional Chinese medicine, has good clinical efficacy in various cardiovascular diseases, this medicine has effects such as blood protection, vascular protection, myocardial protection, stabilizing vulnerable plaques, and vasodilation. However, CVDs are a multifactorial disease, and their underlying mechanisms are not fully understood. Therefore, exploring the mechanism of action and clinical application of Tongxinluo Capsule in the treatment of various cardiovascular diseases is beneficial for exerting its therapeutic effect from multiple components, targets, and pathways. At the same time, it provides broader treatment ideas for other difficult to treat diseases in the cardiovascular event chain, and has significant theoretical and clinical significance for improving the treatment of cardiovascular diseases with traditional Chinese medicine.

As a common cardiovascular disease (CVD), Arrhythmia refers to any abnormality in the origin, frequency, rhythm, conduction velocity, timing, pathway, sequence, or other aspect of cardiac impulses, and it is one of the common cardiovascular diseases in clinical practice. At present, various ion channel blockers are used for treatment of arrhythmia that include Na+ ion channel blockers, K+ ion channel blockers and Ca2+ ion channel blockers. While these drugs offer benefits, they have led to a gradual increase in drug-related adverse reactions across various systems. As a result, the quest for safe and effective antiarrhythmic drugs is pressing. Recent years have seen some advancements in the treatment of ventricular arrhythmias using traditional Chinese medicine(TCM). The theory of Luobing in TCM has proposed a new drug intervention strategy of "fast and slow treatment, integrated regulation" leading to a shift in mindset from "antiarrhythmic" to "rhythm-regulating". Guided by this theory, the development of Shen Song Yang Xin Capsules (SSYX) has involved various Chinese medicinal ingredients that comprehensively regulate the myocardial electrophysiological mechanism, exerting antiarrhythmic effects on multiple ion channels and non-ion channels. Similarly, in clinical studies, evidence-based research has confirmed that SSYX combined with conventional antiarrhythmic drugs can more effectively reduce the occurrence of arrhythmias. Therefore, this article provides a comprehensive review of the composition and mechanisms of action, pharmacological components, network pharmacology analysis, and clinical applications of SSYX guided by the theory of Luobing, aiming to offer valuable insights for improved clinical management of arrhythmias and related research.

Ageing is becoming an increasingly serious problem; therefore, there is an urgent need to find safe and effective anti-ageing drugs. Aims: To investigate the effects of Bazi Bushen capsule (BZBS) on the senescence of mesenchymal stem cells (MSCs) and explore its mechanism of action. Methods: Network pharmacology was used to predict the targets of BZBS in delaying senescence in MSCs. For in vitro studies, MSCs were treated with D-gal, BZBS, and NMN, and cell viability, cell senescence, stemness-related genes, and cell cycle were studied using cell counting kit-8 (CCK-8) assay, SA-β-galactosidase (SA-β-gal) staining, Quantitative Real-Time PCR (qPCR) and flow cytometry (FCM), respectively. Alkaline phosphatase (ALP), alizarin red, and oil red staining were used to determine the osteogenic and lipid differentiation abilities of MSCs. Finally, the expression of senescence-related genes and cyclin-related factors was detected by qPCR and western blotting. Results: Network pharmacological analysis suggested that BZBS delayed cell senescence by interfering in the cell cycle. Our in vitro studies suggested that BZBS could significantly increase cell viability (P < 0.01), decrease the quantity of β-galactosidase+ cells (P < 0.01), downregulate p16 and p21 (P < 0.05, P < 0.01), improve adipogenic and osteogenic differentiation, and upregulate Nanog, OCT4 and SOX2 genes (P < 0.05, P < 0.01) in senescent MSCs. Moreover, BZBS significantly reduced the proportion of senescent MSCs in the G0/G1 phase (P < 0.01) and enhanced the expression of CDK4, Cyclin D1, and E2F1 (P < 0.05, P < 0.01, respectively). Upon treatment with HY-50767A, a CDK4 inhibitor, the upregulation of E2F1 was no longer observed in the BZBS group. Conclusions: BZBS can protect MSCs against D-gal-induced senescence, which may be associated with cell cycle regulation via the Cyclin D1/CDK4/E2F1 signalling pathway.

目的:探讨八子补肾胶囊延缓自然衰老小鼠老化过程的功效作用及作用机制.方法:以13月龄自然衰老小鼠为实验研究对象,将其按体质量随机分为4组,即自然衰老组,八子补肾低、高剂量组(1、2 g·kg-1),雷帕霉素组(0.002 g·kg-1).通过行为学实验检测小鼠的衰弱表征并测定其虚弱指数;流式细胞术检测小鼠脾脏T和B淋巴细胞、效应性T细胞(TE)、记忆性T细胞(TM)、幼稚性T细胞(TN)、辅助性T细胞(Th)、细胞毒性T细胞(Tc)、Th1细胞、Th2细胞和调节性T细胞(Treg)比例;细胞增殖与活性检测(CCK-8)试剂盒检测小鼠淋巴细胞的增殖能力;苏木素-伊红(HE)染色观察小鼠脾脏组织病理学变化;免疫组化法(IHC)检测细胞周期蛋白依赖性激酶抑制剂2A(p16)和细胞周期蛋白依赖性激酶抑制剂1A(p21)的表达情况;实时荧光定量聚合酶链式反应(Real-time PCR)检测衰老相关蛋白p16和p21的mRNA表达情况;Luminex检测小鼠外周血血清炎症因子:肿瘤坏死因子-α(TNF-α)、γ干扰素(IFN-γ)、白细胞介素(IL)-1β、IL-2、IL-4、IL-10、IL-12p70水平.结果:与自然衰老组比较,八子补肾组和雷帕霉素组小鼠的衰弱表征明显改善,虚弱指数评分明显降低(P＜0.05,P＜0.01);脾脏中T细胞、TN细胞、Tc细胞、Th2细胞和Treg细胞比例升高,TE细胞、TM细胞、Th细胞和Th1细胞比例下降(P＜0.05,P＜0.01);脾淋巴细胞增殖能力增强(P＜0.05,P＜0.01);脾脏红髓和白髓边缘区结构清晰,白髓面积增大,红髓面积相应减小;脾脏中衰老相关蛋白p16和p21蛋白表达量减少(P＜0.01);p16和p21的mRNA表达量降低(P＜0.01);血清中促炎细胞因子IL-1β、IL-2、IL-12p70、IFN-γ和TNF-α水平降低,抗炎因子IL-4和IL-10水平升高(P＜0.05,P＜0.01).结论:八子补肾胶囊具有调节自然衰老小鼠衰弱表征,调节机体免疫稳态及炎症水平,减少免疫细胞衰老的作用,起到了延缓衰老的作用功效.

衰老引发的多病失能问题是人口老龄化对经济运行全领域、社会建设各环节、社会文化多方面乃至国家综合实力和国际竞争力均产生深远影响的核心原因.基于中医"治未病"思想,积极应对人口老龄化需要增强预防观念,推进健康老龄化,积极防止老龄人口多病失能问题的出现.将未老先防、已老防衰、已衰防病、已病防失智失能有机结合,通过采取主动抗衰老措施来延缓甚或阻止老龄人口身体功能的减退,以实现老龄人口不得病、少得病、晚得病、不得大病、得病后能够很快康复的健康老龄化的目标,从根本上减轻人口老龄化带来的医疗、保健、养老、居家照护等社会经济压力.

Bazi Bushen (BZBS), a traditional Chinese medicine, has been proven effective in the treatment of age-related disease in mouse models. However, whether its therapeutic effects are due to antiaging mechanism has not yet been explored. In the present study, we investigated the antiaging effects of BZBS in naturally aging mice by using behavioral tests, liver DNA methylome sequencing, methylation age estimation, and frailty index assessment. The methylome analysis revealed a decrease of mCpG levels in the aged mouse liver. BZBS treatment tended to restore age-associated methylation decline and prune the methylation pattern toward that of young mice. More importantly, BZBS significantly rejuvenated methylation age of the aged mice, which was computed by an upgraded DNA methylation clock. These results were consistent with enhanced memory and muscular endurance, as well as decreased frailty score and liver pathological changes. KEGG analysis together with aging-related database screening identified methylation-targeted pathways upon BZBS treatment, including oxidative stress, DNA repair, MAPK signaling, and inflammation. Upregulation of key effectors and their downstream effects on elevating Sod2 expression and diminishing DNA damage were further investigated. Finally, in vitro experiments with senescent HUVECs proved a direct effect of BZBS extracts on the regulation of methylation enzymes during cellular aging. In summary, our work has revealed for the first time the antiaging effects of BZBS by slowing the methylation aging. These results suggest that BZBS might have great potential to extend healthspan and also explored the mechanism of BZBS action in the treatment of age-related diseases.

Aims: To explore the new indications and key mechanism of Bazi Bushen capsule (BZBS) by network pharmacology and in vitro experiment.Methods: The ingredients library of BZBS was constructed by retrieving multiple TCM databases. The potential target profiles of the components were predicted by target prediction algorithms based on different principles, and validated by using known activity data. The target spectrum of BZBS with high reliability was screened by considering the source of the targets and the node degree in compound-target (C-T) network. Subsequently, new indications for BZBS were pre- dicted by disease ontology (DO) enrichment analysis and initially validated by GO and KEGG pathway enrichment analysis. Furthermore, the target sets of BZBS acting on AD signaling pathway were identified by intersection analysis. Based on STRING database, the PPI network of target was constructed and their node degree was calculated. Two Alzheimer's disease (AD) cell models, BV-2 and SH-SY5Y, were used to preliminarily verify the anti-AD efficacy and mechanism of BZBS in vitro.Results: In total, 1499 non-repeated ingredients were obtained from 16 herbs in BZBS formula, and 1320 BZBS targets with high confidence were predicted. Disease enrichment results strongly suggested that BZBS formula has the potential to be used in the treatment of AD. GO and KEGG enrichment results provide a preliminary verification of this point. Among them, 113 functional targets of BZBS belong to AD pathway. A PPI network containing 113 functional targets and 1051 edges for the treatment of AD was constructed. In vitro experiments showed that BZBS could significantly reduce the release of TNF-& alpha; and IL-6 and the expression of COX-2 and PSEN1 in A & beta;25- 35-induced BV-2 cells, which may be related to the regulation of ERK1/2/NF-& kappa;B signaling pathway. BZBS reduced the apoptosis rate of A & beta;25-35 induced SH-SY5Y cells, significantly increased mito- chondrial membrane potential, reduced the expression of Caspase3 active fragment and PSEN1, and increased the expression of IDE. This may be related to the regulation of GSK-3 & beta;/& beta;-catenin signaling pathway. Conclusions: BZBS formula has a potential use in the treatment of AD, which is achieved through regulation of ERK1/2, NF-& kappa;B signaling pathways, and GSK-3 & beta;/& beta;-catenin signaling pathway. Furthermore, the network pharmacology technology is a feasible drug repurposing strategy to reposition new clinical use of approved TCM and explore the mechanism of action. The study lays a foundation for the subsequent in-depth study of BZBS in the treatment of AD and provides a basis for its application in the clinical treatment of AD.

健康状态辨识是实施健康管理的基础和关键环节.以通络养生八字经理论为指导,提出络、精、形、神健康状态辨识——辨络:痰瘀阻络、脉络绌急、寒凝络痹、络虚不荣;辨精:肾精亏虚、精亏骨疏、精亏脑衰、精亏血少;辨形:络息外形、络伤内形;辨神:神伤抑郁、神躁焦虑、神疲健忘、神衰失眠.采用中医诊断方法和现代诊断技术在络、精、形、神4个方面对亚健康和慢病人群的身心健康状况进行全面分析评估,为应用通络养生八字经理论指导健康管理的实施提供前提和依据.

目的 基于网络药理学及分子对接预测连花清咳片治疗新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)可能作用的靶点及信号通路.方法 通过 TCMSP,UniProt Knowledgebase及SwissTargetPrediction数据库获取连花清咳片的活性成分及相关靶点;通过 GeneCards 和 OMIM获取COVID-19 相关靶点;使用Cytoscape 3.9.0 软件构建"连花清咳片-COVID-19"靶点调控网络,结合STRING数据库绘制蛋白相互作用网络(Protein-protein interaction networks,PPI);使用Metascape数据库对交集基因进行GO功能和KEGG通路富集分析.通过 AutoDockTools1.5.6 软件将关键作用靶点与主要活性成分进行分子对接验证.结果 以口服生物利用度(oral bioavailability,OB)和类药性(drug-like proper-ties,DL)作为筛选条件,获得连花清咳片中药物活性成分287 个,药物疾病交集基因 86 个,核心靶点 58 个.KEGG富集分析预测连花清咳片治疗COVID-19 主要涉及p53 信号通路(p53 signaling pathway)、补体途径(complement and coagu-lation cascades)、细胞因子-细胞因子受体相互作用(cyto-kine-cytokine receptor interaction)等信号通路等.分子对接结果证实连花清咳片中主要活性成分与核心靶点具有较为稳定的结合活性.结论 连花清咳片可能通过多成分、多靶点及多通路参与COVID-19 的治疗.

OBJECTIVE To explore the key mechanism of Bazi Bushen capsule(BZBS)in delaying the senescence of mesenchymal stem cells(MSCs)through network pharmacology and in vitro experiments.METHODS Network phar-macology was used to predict the mechanism targets of BZBS in delaying MSCs senescence.A MSCs senescence model induced by D-galac-tose(D-gal)was used to investigate the effect and mechanism of BZBS on MSCs senescence in vitro.RESULTS Network pharmacology analy-sis showed that BZSB could delay MSCs senes-cence.The experiment showed that BZBS could significantly improve the survival activity of the aged MSCs.It significantly reduced the positive rate of β-galactosidase staining and p16,p21 expression in aged MSCs,enhanced the ability of adipogenic differentiation and osteogenic differ-entiation,and increased expression of Nanog,OCT4 and SOX2 in senescent MSCs.CONCLU-SIONS Network pharmacology and in vitro cell experiments verified that BZBS could delay MSCs senescence.

China is at the advanced stage of aging and the degree of aging is increasingly deepening. Thus, China promotes“ positive coping with population aging” to a national strategy and deeply implements the healthy aging strategy. Population aging poses a huge challenge to sustainable development of each aspect of social functioning because senility leads to a decline in the health of the elders. The increasing aging population is bound to bring great pressure on families and the society. Current researches show that anti-aging can significantly improve physical conditions of the elderly, play a positive role in delaying senile disease development and progress and preventing the occurrence of dementia and disability, decrease social demands of aging people, and fundamentally reduce the increasing social burden caused by aging. Anti-aging may become a fundamental measure for actively coping with population aging.

目的 调查并分析居民对衰老及中医药抗衰老的认知和应用现状,为推动中医药抗衰老事业提供参考.方法 在 2022 年 5 月 28 日—2022 年 12 月 16 日对全国 18 岁以上居民采用问卷星线上问卷的形式调查其对衰老及中医药抗衰老的认知和应用情况.回收有效问卷 52 470 份.结果 1)对衰老情况的调查显示,认为自己有衰老表现的参与者占 95.94%,且衰老表现主要在皮肤系统、骨骼肌肉系统、神经精神系统.只有 15.45%的参与者未曾患过衰老相关疾病.交叉分析显示在一定程度上高血压、糖尿病等疾病具有年轻化趋势.2)对衰老了解情况的调查显示,63.76%的参与者经常或偶尔了解衰老知识.58.71%的参与者了解衰老可以延缓并防治.3)对抗衰老态度的调查显示,69.77%的参与者担心衰老,71.57%的参与者认为有必要采取抗衰老措施,认为应该在 31～35 岁开始采取抗衰老措施的参与者最多.交叉分析显示对衰老担心的参与者更愿意了解衰老知识,且认为有必要采取抗衰老措施.4)采取抗衰老措施的调查显示,64.38%的参与者采取过不同类型的抗衰老措施,其中 46.40%的参与者采取过中医药相关的抗衰老措施.5)对中医药抗衰老产品认知和关注态度的调查结果显示,40.60%的参与者认为应该在 1 年内感知到明显效果,选择时最关注的4个因素是自身需求程度、服用方式、药效药理作用和说明书适应症,最受欢迎的服用剂型是口服液(65.38%).6)对中医药抗衰老综合看法的调查显示,78.74%的参与者认为中医药抗衰老整体需要进一步发展.94.90%的参与者不了解中医药抗衰老理论.受关注更多的方面是加强科普知识的宣传、人才培养和产品研发.结论 调查可知衰老表现和衰老相关疾病的发生年龄趋向年轻化,抗衰老迫在眉睫.然而民众对衰老和中医药抗衰老知识的了解程度较低且缺乏规范的了解渠道,抗衰老措施的知晓度、应用率也有待提高.中医药抗衰老的理论构建、科普宣传、人才培养、产品研发和科学研究等有待全面发展.希望此次调查及建议能够为抗衰老研究人员提供参考,推动健康老龄化的发展进程.

基于中医气血相关理论,络病理论提出脑之气络与脉络相偕而行,在结构和功能方面"唇齿相依",为脑主神明功能的重要基础;提出络气虚滞/郁滞、脉络瘀阻、神识失用为阿尔茨海默病主要病机,有别于现代医学重点关注神经元的研究策略;提出从神经元保护——清除β-淀粉样蛋白、磷酸化tau蛋白等病理产物和脑微血管保护——脑微血管结构与功能保护、促进治疗性血管新生、增加脑血流2个方面治疗阿尔茨海默病的必要性.在"络以通为用"治疗原则指导下研制的通络代表药物通心络胶囊具有微血管保护优势,可发挥血管保护介导的神经保护作用,临床研究证实其可有效治疗阿尔茨海默病、血管性痴呆及认知障碍相关疾病,可为从神经-血管保护全面防治阿尔茨海默病提供新思路和新途径.